

# **Tracking the Invisible**

**a probabilistic approach to  
field cancerization**

**Marc D. Ryser**

**Department of Mathematics  
Duke University**

# Collaborators

- Rick Durrett (Duke)
- Jasmine Foo (U of Minnesota)
- Kevin Leder (U of Minnesota)

**Motivation**

**a clinical problem**


# Diagnosis



- Patient presents with tongue cancer

# Treatment




1. Surgical resection
2. Check margin An arrow points from the text 'Check margin' to a diagram consisting of a solid dark blue circle surrounded by a dashed white circle, representing the surgical margin.
3. Follow-up therapy:  
radiation and/or  
chemotherapy

# Resected tongue cancer



# Resected tongue cancer




tumor

margin

Frequent recurrence of disease  
(20-30%)...



... 1-5 years later




Resected portion



Local recurrence

... 1-5 years later



Resected portion




Local recurrence

But margin was tumor free...  
why the new tumor?



precancer field




Resected portion



Local recurrence



precancer field




Resected portion



Local recurrence



precancer field




Resected portion



Local recurrence




precancer field



Resected portion




Local recurrence








precancer field



Resected portion



Local recurrence



# **The Problem**

**field cancerization**



# Field Cancerization

- Malignant tumor is surrounded by precancerous 'field'
- Not visible to surgeon
- 'Field': high risk of progression



# Field Cancerization

- Present in most skin-cancers (carcinomas)
- Head and neck, lung, bladder
- Also: breast, colon, cervix, etc

# Invisibility = Uncertainty


- Surgeon: how much margin around tumor?
- Distant field present at diagnosis?
- Risk of progression - surveillance protocol?

# Invisibility = Uncertainty

- Surgeon: how much margin around tumor?
- Distant field present at diagnosis?
- Risk of progression - surveillance protocol?

Can we develop a mechanistic, dynamic model to answer these questions?

# The Model





- Non-spatial model: branching process
- Here, geometry matters!





cross-section of epithelium

# Cellular dynamics



- maturation
- post-mitotic
- stem

# Cellular dynamics



- maturation
- post-mitotic
- stem


Focus on basal layer



# Focus on basal layer



Cells



- Spatial evolutionary dynamics
- Cell of type  $i$ : stochastic division @ rate  $f_i$
- Replace neighbor (unif. at random)

# Growth dynamics of mutant progeny

Movie 1

sped-up process


Movie 2

Add mutations

Movie 3

Movie 4

# Add mutations: multistep carcinogenesis




# Biased voter model



Jasmine Foo's talk

# Mesososcopic model



# **Model Analysis**

# Assumptions

- 3 cell types: normal cells, precancerous cells and malignant cells
- General dimension  $d \geq 1$






- New precancer fields: Poisson arrivals
- Fields grow at constant radial rate
- Each field: non-homogeneous Poisson process to yield a tumor clone


# Important notion: size-biased pick

**Definition 3.1** (Size-biased pick). Let  $L_1, \dots, L_n$  be a family of  $n$  random variables. A size-biased pick from  $L_1, \dots, L_n$  is defined as a random variable  $L_{[1]}$  with conditional probability distribution

$$P(L_{[1]} = L_i | L_1, \dots, L_n) = L_i / \sum_{j=1}^n L_j.$$



# Local field area




**Theorem 0.1.** *The distribution of the area of the local field at time of tumor initiation  $\sigma_2$ , conditioned on  $\{\sigma_2 \in dt\}$ , is given by*

$$\hat{P}(X_t(\sigma_2) \in dx) = \hat{P}(X_{[1]} \in dx) = \frac{u_2 \bar{s}_2 x^{1/d}}{d \gamma_d^{1/d} c_d(s_1) (1 - e^{-\theta t^{d+1}})} \exp \left[ \frac{-u_2 \bar{s}_2 x^{\frac{d+1}{d}}}{(d+1) \gamma_d^{1/d} c_d(s_1)} \right],$$

for  $x \in [0, \gamma_d c_d^d(s_1) t^d]$ .

# Distant field area



$\bar{X}_d$

**Theorem 0.2.** *The size-distribution of the distant field clones at time of tumor initiation  $\sigma_2$ , conditioned on  $\{\sigma_2 = t\}$ , is given by*

$$\begin{aligned} \mathcal{L}(\bar{X}_d | t \in dt) &= {}_d \hat{P}(\tilde{X}_1 \in dx_1, \dots, \tilde{X}_{M(t)-1} \in dx_{M(t)-1}) \\ &= \frac{1}{1 - e^{-\lambda t \phi(t)}} \sum_{m=1}^{\infty} \frac{(\lambda \phi(t) t)^m e^{-\lambda \phi(t) t}}{m!} \prod_{i=1}^{m-1} g_t(x_i), \end{aligned}$$

where

$$g_t(x) \equiv \frac{x^{1/d-1}}{d \gamma_d^{1/d} c_d(s_1) t \phi(t)} \exp \left[ \frac{-u_2 \bar{s}_2 x^{\frac{d+1}{d}}}{(d+1) \gamma_d^{1/d} c_d(s_1)} \right].$$

## Key insight from these results:

How do microscopic parameters (cellular fitness, mutation rates etc) influence the geometry of the invisible precancer fields.

## Key insight from these results:

How do microscopic parameters (cellular fitness, mutation rates etc) influence the geometry of the invisible precancer fields.

Now, let's go back to the clinical issues outlined in the beginning...


# Excision Margin I



How big should the margin be to avoid recurrence from unresected portion of the field?

# Excision Margin II

## Cumulative incidence of second field tumor




diam=diameter of excised portion



# Excision Margin III




## Probability of recurrence



# Recurrence: local vs distant

- At time  $T=0$ , remove the tumor
- Time to distant recurrence?
- Time to local recurrence?





# Reference

Foo, Leder, Ryser (2014)

Journal of Theoretical Biology


# Ongoing Work

With Drs. Lee, Ready, and Shealy (Duke Medicine)

# Added complexity

- Beyond the 2-step model
- Collect clinical data for validation/  
refinement
- Goal: patient-specific predictions via  
integrated data-modeling framework

**Patient data**  
spectroscopic probe  
imaging  
biopsies



**Mathematical Model**



*That's all Folks!*